Vital Therapies +30% Premarket as Co Announces Additional Data from VTI-208 Presentation at Rostock Conference

Vital Therapies, Inc.

today announced that additional data from its VTI-208 clinical trial were presented by two principal investigators of the study at the 16th International Symposium on Albumin Dialysis in Liver Disease on Saturday, August 29, 2015 in Rostock-Warnemunde, Germany. The conference's focus this year is: "Artificial and Bio-artificial Liver Support-Mechanisms of Action and Clinical Effects." Topline data from the VTI-208 clinical trial, which failed to reach its primary or secondary endpoints, was disclosed on August 21, 2015. The presentations, titled "Acute Alcoholic Hepatitis and Liver Support," and "Appropriate Patient Selection as a Key to Increase Benefit/Risk Ratio for ELAD", were made by Julie Thompson, MD, M.P.H., Assistant Professor of Medicine, Gastroenterology Division, University of Minnesota, and Ram M. Subramanian, MD, Associate Professor of Medicine and Surgery, Emory University School of Medicine. Drs. Thompson and Subramanian were the two highest enrolling principal investigators in the VTI-208 clinical trial with 17 subjects each. Newly presented information includes: A review of baseline characteristics and demographics of two of the pre-specified subsets: